Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 17/20 | 0.63 |
| ▸ | PTGDR | Q13258 | 5/20 | 0.48 |
| ▸ | PRNP | P04156 | 4/20 | 0.48 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.45 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12243401 | 0.97 | PTGIR (0.62) | PTGIRPTGDRPRNPSLC16A3SLC16A1 | |
| SCHEMBL2374594 | 0.97 | PTGIR (0.65) | PTGIRPTGDRPRNP | |
| SCHEMBL12243376 | 0.97 | PTGIR (0.65) | PTGIRPTGDRPRNP | |
| SCHEMBL2377063 | 0.97 | PTGIR (0.62) | PTGIRPTGDRPRNPSLC16A3SLC16A1 | |
| SCHEMBL2374592 | 0.97 | PTGIR (0.65) | PTGIRPTGDRPRNP | |
| SCHEMBL2377060 | 0.97 | PTGIR (0.62) | PTGIRPTGDRPRNPSLC16A3SLC16A1 | |
| SCHEMBL12243426 | 0.88 | PTGIR (0.66) | PTGIRPTGDRPRNP | |
| SCHEMBL2375586 | 0.88 | PTGIR (0.66) | PTGIRPTGDRPRNP | |
| SCHEMBL2375579 | 0.88 | PTGIR (0.66) | PTGIRPTGDRPRNP | |
| SCHEMBL13332530 | 0.87 | PTGIR (0.64) | PTGIRPTGDRPRNPSLC16A3SLC16A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689372-B2 | Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190270731-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2019-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689372-B2 | Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | PTGIR, PTGIS, PTGER1 | PTGIR 1/4885PTGDR 19/4885PRNP 2348/4885 |
| US-20190270731-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER1 | PTGIR 1/4885PTGDR 19/4885PRNP 2348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.